Novartis Leaves Door Open to Higher Offer for Alcon
Novartis AG Chief Executive Officer Joe Jimenez left open the possibility the Swiss drugmaker may raise its $9.8 billion offer to buy out eye-care company Alcon Inc.’s minority shareholders.
New BioTrends Report Highlights The Current Treatment Approaches And Major Drivers Of Prescribing Choice For ...
BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Noninfectious Uveitis. This report, based on feedback gathered in an on-line survey completed by 72 retinal specialists in June/July 2010, addresses the medical management of noninfectious uveitis (anterior, intermediate, posterior and panuveitis) and referral/co-management ...
|
